样式: 排序: IF: - GO 导出 标记为已读
-
Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022). J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-08-15 Hong You,Fusheng Wang,Taisheng Li,Xiaoyuan Xu,Yameng Sun,Yuemin Nan,Guiqiang Wang,Jinlin Hou,Zhongping Duan,Lai Wei,Jidong Jia,Hui Zhuang,
To facilitate the achieving of the goal of "eliminating viral hepatitis as a major public health threat by 2030" set by the World Health Organization, the Chinese Society of Hepatology together with the Chinese Society of Infectious Diseases (both are branches of the Chinese Medical Association) organized a panel of experts and updated the guidelines for prevention and treatment of chronic hepatitis
-
IGF2BP3 Enhances the Growth of Hepatocellular Carcinoma Tumors by Regulating the Properties of Macrophages and CD8+ T Cells in the Tumor Microenvironment. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-08-01 Lingyu Ma,Jiayu Jiang,Qin Si,Chong Chen,Zhaojun Duan
Background and Aims Overexpression of IGF2BP3 is associated with the prognosis of hepatocellular carcinoma (HCC). However, its role in regulating tumor immune microenvironment (TME) is not well characterized. Here, we investigated the effects of IGF2BP3 on macrophages and CD8+ T cells within the TME of HCC. Methods The relationship between IGF2BP3 and immune cell infiltration was analyzed using online
-
Molecular Detection of FGFR2 Rearrangements in Resected Intrahepatic Cholangiocarcinomas: FISH Could Be An Ideal Method in Patients with Histological Small Duct Subtype. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-07-27 Yining Zou,Kun Zhu,Yanrui Pang,Jing Han,Xin Zhang,Zhengzeng Jiang,Yufeng Huang,Wenyi Gu,Yuan Ji
Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a subtype of primary liver cancer for which effective therapeutic agents are lacking. Fibroblast growth factor receptor 2 (FGFR2) has become a promising therapeutic target in ICC; however, its incidence and optimum testing method have not been fully assessed. This study investigated the rearrangement of FGFR2 in intrahepatic cholangiocarcinoma
-
Distinct Types of Cell Death and Implications in Liver Diseases: An Overview of Mechanisms and Application. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-07-24 Yukun Wang,Chunxia Shi,Jin Guo,Yanqiong Zhang,Zuojiong Gong
Cell death is associated with a variety of liver diseases, and hepatocyte death is a core factor in the occurrence and progression of liver diseases. In recent years, new cell death modes have been identified, and certain biomarkers have been detected in the circulation during various cell death modes that mediate liver injury. In this review, cell death modes associated with liver diseases are summarized
-
Clinical Significance of Apurinic/Apyrimidinic Endodeoxyribonuclease 1 and MicroRNA Axis in Hepatocellular Carcinoma. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-07-17 Giovanna Mangiapane,Devis Pascut,Emiliano Dalla,Giulia Antoniali,Monica Degrassi,Lory Saveria Crocè,Veronica De Sanctis,Silvano Piazza,Giulia Canarutto,Claudio Tiribelli,Gianluca Tell
Background and Aims Identification of prognostic factors for hepatocellular carcinoma (HCC) opens new perspectives for therapy. Circulating and cellular onco-miRNAs are noncoding RNAs which can control the expression of genes involved in oncogenesis through post-transcriptional mechanisms. These microRNAs (miRNAs) are considered novel prognostic and predictive factors in HCC. The apurinic/apyrimidinic
-
Proanthocyanidin Alleviates Liver Ischemia/Reperfusion Injury by Suppressing Autophagy and Apoptosis via the PPARα/PGC1α Signaling Pathway. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-07-17 Zhilu Yao,Ning Liu,Hui Lin,Yingqun Zhou
Background and Aims Hepatic ischemia-reperfusion injury (IRI) is a common pathophysiological phenomenon in clinical practice, which usually occurs in liver transplantation, liver resection, severe trauma, and hemorrhagic shock. Proanthocyanidin (PC), exerted from various plants with antioxidant, antitumor, and antiaging activity, were administrated in our study to investigate the underlying mechanism
-
Development and Validation of a Clinical Risk Score to Predict Immune-mediated Liver Injury Caused by Sintilimab: Assessed for Causality Using Updated RUCAM. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-07-07 Caiyun Zheng,Shunmin Huang,Meimei Lin,Baohui Hong,Hengfen Dai,Jing Yang
Background and Aims Immune-mediated liver injury is a fatal side effect of sintilimab. This study aimed to shed light on the associated risk factors and characteristics of this adverse event. Methods The clinical records of 772 patients treated with sintilimab were retrospectively reviewed to investigate risk factors associated with sintilimab immune-related hepatotoxicity, as well as its incidence
-
Prognostic Performance of the China Liver Cancer Staging System in Hepatocellular Carcinoma Following Transarterial Chemoembolization. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-07-07 Bin-Yan Zhong,Jian-Qiang Jiang,Jun-Hui Sun,Jin-Tao Huang,Wei-Dong Wang,Qi Wang,Wen-Bin Ding,Xiao-Li Zhu,Cai-Fang Ni
Background and Aims To validate prognostic performance of the China liver cancer (CNLC) staging system as well as to compare these parameters with those of the Barcelona Clinic Liver Cancer (BCLC) staging system for Chinese hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE). Methods This multicenter retrospective study included 1,124 patients with HCC between January
-
A Cross-sectional Real-life Study of the Prevalence, Severity, and Determinants of Metabolic Dysfunction-associated Fatty Liver Disease in Type 2 Diabetes Patients. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-06-30 Quentin Binet,Audrey Loumaye,Michel P Hermans,Nicolas Lanthier
Background and Aims Most data on liver assessment in type 2 diabetes mellitus (T2DM) patients are from retrospective cohorts with selection bias. We aimed at appraising the feasibility, results, and benefits of an outpatient systematic noninvasive screening for metabolic dysfunction-associated fatty liver disease (MAFLD) severity and determinants in T2DM patients. Methods We conducted a 50-week cross-sectional
-
Early but Not Late Exercise Training in Mice Exacerbates Hepatic Inflammation in Developing Nonalcoholic Fatty Liver Disease. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-06-19 Artemiy Kovynev,Zhixiong Ying,Joost M Lambooij,Hendrik J P van der Zande,Bruno Guigas,Patrick C N Rensen,Milena Schönke
-
Performance of Hepatitis Delta Virus (HDV) RNA Testing for the Diagnosis of Active HDV Infection: Systematic Review and Meta-analysis. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-06-14 Sisi Chen,Xiangying Zhang,Ling Xu,Yuan Tian,Zihao Fan,Yaling Cao,Zhenzhen Pan,Yao Gao,Sujun Zheng,Zhongping Duan,Mei Liu,Feng Ren
Background and Aims Hepatitis delta virus (HDV) is a defective virus and causes severe liver disease. Several HDV RNA assays have been developed, however the diagnostic efficacy remains unclear.This systematic review and meta-analysis aims to evaluate the diagnostic accuracy of HDV RNA assays to aid in the diagnosis of active hepatitis D. Methods The PubMed, Embase, and Cochrane Library databases were
-
CENPA-driven STMN1 Transcription Inhibits Ferroptosis in Hepatocellular Carcinoma. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-06-12 Daomiao Liang,Lanzhu Luo,Jiang Wang,Tongyu Liu,Chao Guo
Background and Aims The growing knowledge of ferroptosis has suggested the regulatory role of ferroptosis in hepatocellular carcinoma (HCC), but the pertinent molecular mechanisms remain unclear. Herein, this study investigated the mechanistic basis of ferroptosis-related genes (ferrGenes) in the growth of HCC. Methods Differentially expressed human ferrGenes and tumor-related transcription factors
-
Carvedilol Versus Other Nonselective Beta Blockers for Variceal Bleeding Prophylaxis and Death: A Network Meta-analysis. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-06-08 Ka-Shing Cheung,Chiu-Hang Mok,Lok-Ka Lam,Xian-Hua Mao,Lung-Yi Mak,Wai-Kay Seto,Man-Fung Yuen
Background and Aims We aimed to perform a network meta-analysis (NWM) to examine comparative effectiveness of non-selective beta blockers (NSBBs) on prophylaxis of gastroesophageal variceal bleeding (GVB) and mortality benefit. Methods MEDLINE (OVID) and EMBASE databases were searched for eligible randomized clinical trials (RCTs) from inception to July 3, 2021. Outcomes of interest included primary/secondary
-
High Frequency of Antiviral Resistance Mutations in HBV Genotypes A2 and H: Multidrug Resistance Strains in Mexico. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-06-07 Alexis Jose-Abrego,Sonia Roman,João Renato Rebello Pinho,Michele Soares Gomes-Gouvêa,Arturo Panduro
Background and Aims Lamivudine (3TC), telbivudine (LdT), entecavir (ETV), adefovir (ADF), and tenofovir (TFV) are drugs used to treat hepatitis B virus (HBV) infection, but specific mutations allow some viruses to become resistant to antiviral drugs or to acquire immune escape capacities. These mutations have not been thoroughly investigated in Mexico. This study aimed to estimate the prevalence of
-
NASH Drug Development: Seeing the Light at the End of the Tunnel? J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-06-05 Yong Q Chen
Nonalcoholic steatohepatitis (NASH) is a chronic liver disease affecting a large population worldwide. No clinically approved drugs are available. In this minireview, we discuss the heterogeneous nature of NASH and lack of consensus in outcome measures among clinical trials. We summarize NASH therapeutic targets and candidate drugs. We compare the efficacy of 33 published clinical trials that evaluated
-
Fucoidan Ameliorates Ferroptosis in Ischemia-reperfusion-induced Liver Injury through Nrf2/HO-1/GPX4 Activation. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-06-02 Jing-Jing Li,Wei-Qi Dai,Wen-Hui Mo,Wen-Qiang Xu,Yue-Yue Li,Chuan-Yong Guo,Xuan-Fu Xu
Background and Aims Liver ischemia-reperfusion (IR) injury is a common pathological process in liver surgery. Ferroptosis, which is closely related to lipid peroxidation, has recently been confirmed to be involved in the pathogenesis of IR injury. However, the development of drugs that regulate ferroptosis has been slow, and a complete understanding of the mechanisms underlying ferroptosis has not
-
Integrated Multidisciplinary Management of Alcohol-associated Liver Disease. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-06-02 Malia Holbeck,Hannah Statz DeVries,Ashwani K Singal
Alcohol-associated liver disease (ALD) is one of the most common liver diseases and indications for liver transplantation (LT). Alcohol use disorder (AUD), a frequent accompaniment in ALD patients, may also be associated with psychiatric comorbidities such as depression and anxiety. Identification of ALD at an earlier stage, and treatment of AUD may help prevent progression to advanced stage of ALD
-
Portal Hypertension in Nonalcoholic Fatty Liver Disease: Challenges and Paradigms. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-05-31 Emilie K Mitten,Piero Portincasa,György Baffy
Portal hypertension in cirrhosis is defined as an increase in the portal pressure gradient (PPG) between the portal and hepatic veins and is traditionally estimated by the hepatic venous pressure gradient (HVPG), which is the difference in pressure between the free-floating and wedged positions of a balloon catheter in the hepatic vein. By convention, HVPG≥10 mmHg indicates clinically significant portal
-
Liver Fat Scores for Noninvasive Diagnosis and Monitoring of Nonalcoholic Fatty Liver Disease in Epidemiological and Clinical Studies. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-05-31 Mona Reinshagen,Stefan Kabisch,Andreas F H Pfeiffer,Joachim Spranger
Nonalcoholic fatty liver disease (NAFLD) is strongly associated with the metabolic syndrome and type 2 diabetes and independently contributes to long-term complications. Being often asymptomatic but reversible, it would require population-wide screening, but direct diagnostics are either too invasive (liver biopsy), costly (MRI) or depending on the examiner's expertise (ultrasonography). Hepatosteatosis
-
Hepatitis Virus-associated Non-hodgkin Lymphoma: Pathogenesis and Treatment Strategies. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-05-30 Wenjing Zhang,Fan Du,Li Wang,Tao Bai,Xiang Zhou,Heng Mei
Over the last decade, epidemiological studies have discovered a link between hepatitis C virus (HCV) and hepatitis B virus (HBV) infection and non-Hodgkin lymphoma (NHL). The regression of HCV-associated NHL after HCV eradication is the most compelling proof supporting HCV infection's role in lymphoproliferative diseases. HBV infection was found to significantly enhance the incidence of NHL, according
-
Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-05-24 Jee-Fu Huang,Pei-Chien Tsai,Ming-Lun Yeh,Chung-Feng Huang,Ching-I Huang,Mei-Hsuan Lee,Po-Yau Hsu,Chih-Wen Wang,Yu-Ju Wei,Po-Cheng Liang,Yi-Hung Lin,Meng-Hsuan Hsieh,Jeng-Fu Yang,Ming-Yen Hsieh,Tyng-Yuan Jang,Ming-Jong Bair,Zu-Yau Lin,Chia-Yen Dai,Ming-Lung Yu,Wan-Long Chuang
Background and Aims Disease severity across the different diagnostic categories of metabolic dysfunction-associated fatty liver disease (MAFLD) remains elusive. This study assessed the fibrosis stages and features of MAFLD between different items. We also aimed to investigate the associations between advanced fibrosis and risk factors. Methods This multicenter cross-sectional study enrolled adults
-
Activation of NLRP3 Inflammasome via Drp1 Overexpression in Kupffer Cells Aggravates Ischemia-reperfusion Injury in Hepatic Steatosis. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-05-23 Lu Zhang,Mingfu Wang,Ran An,Jun Dai,Shujun Liu,Ming Chen,Haoran Ding
Background and Aims Donors with fatty livers are considered to address the shortage of livers for transplantation, but those livers are particularly sensitive to ischemia-reperfusion injury (IRI), and an increased incidence of graft failure is observed. Kupffer cells account for 20-35% of liver nonparenchymal cells, and have been shown to participate in the process of IRI and inflammatory reactions
-
Current Status and Analysis of Machine Learning in Hepatocellular Carcinoma. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-05-17 Sijia Feng,Jianhua Wang,Liheng Wang,Qixuan Qiu,Dongdong Chen,Huo Su,Xiaoli Li,Yao Xiao,Chiayen Lin
Hepatocellular carcinoma (HCC) is a common tumor. Although the diagnosis and treatment of HCC have made great progress, the overall prognosis remains poor. As the core component of artificial intelligence, machine learning (ML) has developed rapidly in the past decade. In particular, ML has become widely used in the medical field, and it has helped in the diagnosis and treatment of cancer. Different
-
Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma: Real-life Data on Liver Disease, Treatment and Prognosis. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-05-16 Xavier Adhoute,Olivia Pietri,Guillaume Pénaranda,Thomas Wolf,Patrick Beaurain,Olivier Monnet,Arthur Laquière,Justine Bonomini,Frédéric Neumann,Olivier Levrel,Jean-Pascal Buono,Xavier Hanna,Paul Castellani,Hervé Perrier,Marc Bourliere,Rodolphe Anty
Background and Aims Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) have common features and differences. This real-life study investigated their characteristics, treatment modalities, and prognoses. Methods This retrospective comparative study was performed in 1,075 patients seen at one tertiary center between January 2008 and December 2020. Overall survival (OS) was estimated
-
Emerging Evidence Linking the Liver to the Cardiovascular System: Liver-derived Secretory Factors. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-05-12 Xiang Liu,Yijia Shao,Linjiang Han,Ruyue Zhang,Jimei Chen
Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide. Recently, accumulating evidence has revealed hepatic mediators, termed as liver-derived secretory factors (LDSFs), play an important role in regulating CVDs such as atherosclerosis, coronary artery disease, thrombosis, myocardial infarction, heart failure, metabolic cardiomyopathy, arterial hypertension, and
-
Noninvasive Fibrosis Assessment in Chronic Hepatitis C Infection: An Update. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-05-11 Kristina Bojanic,Mirta Sudaric Bogojevic,Sonja Vukadin,Renata Sikora,Gordana Ivanac,Nikola Raguz Lucic,Martina Smolic,Ashraf A Tabll,George Y Wu,Robert Smolic
Liver biopsy is historically the gold standard for liver fibrosis assessment of chronic hepatitis C patients. However, with the introduction and validation of noninvasive tests (NITs) to evaluate advanced fibrosis, and the direct-acting antiviral agents for treatment of chronic hepatitis C virus (HCV), the role of NITs have become even more complex. There is now need for longitudinal monitoring and
-
Roles and Molecular Mechanisms of Biomarkers in Hepatocellular Carcinoma with Microvascular Invasion: A Review. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-05-04 Xudong Zhao,Yudan Wang,Haoming Xia,Shuqiang Liu,Ziyue Huang,Risheng He,Liang Yu,Nanfeng Meng,Hang Wang,Junqi You,Jinglin Li,Judy Wai Ping Yam,Yi Xu,Yunfu Cui
Hepatocellular carcinoma (HCC) being a leading cause of cancer-related death, has high associated mortality and recurrence rates. It has been of great necessity and urgency to find effective HCC diagnosis and treatment measures. Studies have shown that microvascular invasion (MVI) is an independent risk factor for poor prognosis after hepatectomy. The abnormal expression of biomacromolecules such as
-
Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-04-28 Takashi Kobayashi,Michihiro Iwaki,Asako Nogami,Masato Yoneda
Drug-induced liver injury (DILI) is a major cause of acute liver injury, liver failure, and liver transplantation worldwide. In recent years, immune checkpoint inhibitors have become widely used. This has led to an increase in DILI, for which pathophysiology and management methods differ significantly from the past. As the number of cases of acute liver injury and liver transplantation due to DILI
-
Serum Soluble Vascular Endothelial Growth Factor Receptor 1 as a Potential Biomarker of Hepatopulmonary Syndrome. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-04-24 Yu-Jie Li,Xian-Feng Wu,Dan-Dan Wang,Peng Li,Hao Liang,Xiao-Yan Hu,Jia-Qi Gan,Yi-Zhu Sun,Jun-Hong Li,Jun Li,Xin Shu,Ai-Lin Song,Chun-Yong Yang,Zhi-Yong Yang,Wei-Feng Yu,Li-Qun Yang,Xiao-Bo Wang,Karine Belguise,Zheng-Yuan Xia,Bin Yi
Background and Aims The results of basic research implicate the vascular endothelial growth factor (VEGF) family as a potential target of hepatopulmonary syndrome (HPS). However, the negative results of anti-angiogenetic therapy in clinical studies have highlighted the need for markers for HPS. Therefore, we aimed to determine whether VEGF family members and their receptors can be potential biomarkers
-
High-intensity Interval Training for the Management of Nonalcoholic Steatohepatitis: Participant Experiences and Perspectives. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-04-21 Shelley E Keating,Ilaria Croci,Matthew P Wallen,Emily R Cox,Jeff S Coombes,Nicola W Burton,Graeme A Macdonald,Ingrid J Hickman
Background and Aims High-intensity interval training (HIIT) is a therapeutic option for people with nonalcoholic steatohepatitis (NASH). However, the perspectives and experiences of HIIT for people with NASH are unknown, limiting translation of research. We explored the experiences and perspectives of both professionally supervised and self-directed HIIT in people with NASH and evaluated participant-reported
-
Dysregulation of PLOD2 Promotes Tumor Metastasis and Invasion in Hepatocellular Carcinoma. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-04-21 Keren Li,Yi Niu,Kai Li,Chengrui Zhong,Zhiyu Qiu,Yichuan Yuan,Yunxing Shi,Zhu Lin,Zhenkun Huang,Dinglan Zuo,Yunfei Yuan,Binkui Li
Background and Aims Metastasis is a major factor associated with high recurrence and mortality in hepatocellular carcinoma (HCC) patients while the underlying mechanism of metastasis remains elusive. In our study, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) was shown to be involved in the process of metastasis in HCC. Methods The Cancer Genome Atlas (TCGA) database and HCC tissue microarrays
-
Therapeutic Effect of Prolyl Endopeptidase Inhibitor in High-fat Diet-induced Metabolic Dysfunction-associated Fatty Liver Disease. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-04-19 Jian-Bin Zhang,Meng-Ting Li,Shuang-Zhe Lin,Yu-Qing Cheng,Jian-Gao Fan,Yuan-Wen Chen
Background and Aims Prolyl endopeptidase (PREP) is a serine endopeptidase that participates in many pathological processes including inflammation, oxidative stress, and autophagy. Our previous studies found that PREP knockout exhibited multiple benefits in high-fat diet (HFD) or methionine choline-deficient diet-induced metabolic dysfunction-associated fatty liver disease (MAFLD). However, cumulative
-
Current Therapeutics in Primary Sclerosing Cholangitis. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-04-17 Natassia Tan,John Lubel,William Kemp,Stuart Roberts,Ammar Majeed
Primary sclerosing cholangitis (PSC) is an orphan, cholestatic liver disease that is characterized by inflammatory biliary strictures with variable progression to end-stage liver disease. Its pathophysiology is poorly understood. Chronic biliary inflammation is likely driven by immune dysregulation, gut dysbiosis, and environmental exposures resulting in gut-liver crosstalk and bile acid metabolism
-
Metabolic Phenotypes: Drivers of Health Outcomes in Fatty Liver Diseases. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-04-17 Phunchai Charatcharoenwitthaya
-
Functional Cure of Chronic Hepatitis B with Antiviral Treatment in Children having High-level Viremia and Normal or Mildly Elevated Serum Aminotransferase. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-04-10 Jing Li,Peiyao Fan,Zhiqiang Xu,Yi Dong,Fuchuan Wang,Weiguo Hong,Jinfang Zhao,Yinjie Gao,Jianguo Yan,Lili Cao,Chao Zhang,Shishu Zhu,Fu-Sheng Wang,Min Zhang
Background and Aims There is a lack of data supporting the notion that antiviral treatments can benefit children with chronic hepatitis B (CHB) having high viremia and normal or mildly elevated serum alanine aminotransferase (ALT) levels. We aimed to analyze the efficacy of antiviral treatments in children with CHB and explore the factors associated with functional cure. Methods Forty-eight children
-
Diagnostic and Prognostic Value of Protein Post-translational Modifications in Hepatocellular Carcinoma. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-04-04 Jing Wang,Fangfang Wang,Ning Wang,Mei-Yin Zhang,Hui-Yun Wang,Guo-Liang Huang
Hepatocellular carcinoma (HCC) is a common malignant tumor with high incidence and cancer mortality worldwide. Post-translational modifications (PTMs) of proteins have a great impact on protein function. Almost all proteins can undergo PTMs, including phosphorylation, acetylation, methylation, glycosylation, ubiquitination, and so on. Many studies have shown that PTMs are related to the occurrence
-
Histopathological Features Predicting Long-term Clinical Outcomes in Patients with Vanishing Bile Duct Syndrome. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-04-04 Tingting Lv,Haitian Yu,Xiao Han,Aileen Wee,Jimin Liu,Min Li,Jinghang Xu,Xiaoli Hu,Jia Li,Weijia Duan,Tailing Wang,Jidong Jia,Xinyan Zhao
Background and Aims The clinicopathological features and long-term outcomes of patients with vanishing bile duct syndrome (VBDS) have yet to be elucidated. The study aims to investigate these features and identify factors associated with poor prognosis. Methods This multicenter retrospective study recruited patients with liver biopsy-proven VBDS who were followed up at five hospitals in northern China
-
Exosome-transported circHDAC1_004 Promotes Proliferation, Migration, and Angiogenesis of Hepatocellular Carcinoma by the miR-361-3p/NACC1 Axis. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-03-22 Bin Xu,Wenbo Jia,Yanzhi Feng,Jinyi Wang,Jing Wang,Deming Zhu,Chao Xu,Litao Liang,Wenzhou Ding,Yongping Zhou,Lianbao Kong
Background and Aims Hepatocellular carcinoma (HCC) is among the most common malignant tumors globally. Circular RNAs (circRNAs), as a type of noncoding RNAs, reportedly participate in various tumor biological processes. However, the role of circHDAC1_004 in HCC remains unclear. Thus, we aimed to explore the role and the underlying mechanisms of circHDAC1_004 in the development and progression of HCC
-
R0 Liver Resection should be a First-line Treatment for Selected Patients with Intermediate Hepatocellular Cancer. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-03-17 Martin Janicko,Sylvia Drazilova,Peter Jarcuska
-
IL-33 Downregulates Hepatic Carboxylesterase 1 in Acute Liver Injury via Macrophage-derived Exosomal miR-27b-3p. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-03-16 Ping Gao,Min Li,Jingli Lu,Daochun Xiang,Ximin Wang,Yanjiao Xu,Yue Zu,Xinlei Guan,Guodong Li,Chengliang Zhang
Background and Aims We previously reported that carboxylesterase 1 (CES1) expression was suppressed following liver injury. The study aimed to explore the role of interleukin (IL)-33 in liver injury and examine the mechanism by which IL-33 regulates CES1. Methods IL-33 and CES1 levels were determined in the livers of patients and lipopolysaccharide (LPS)-, acetaminophen (APAP)-treated mice. We constructed
-
Single-cell RNA-seq Revealed that Altered Tumor Infiltrating Lymphocytes in Cirrhotic Liver Indicate Development of Hepatocellular Carcinoma. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-03-16 Jingxian Duan,Peng Zhu,Yong Zhang,Tianhao Mu,Yingqiang Li,Rui Xiong,Su Chen,Yingmei Li,Zhicheng Li,Shifu Chen,Lei Zhang
Background and Aims Cirrhosis is the precursor lesion for most hepatocellular carcinoma (HCC) cases. However, no biomarker effectively predicted HCC initiation before diagnosis by imaging. We aimed to investigate the hallmarks of immune microenvironments in healthy, cirrhotic livers and HCC tumor tissues and to identify immune biomarkers of cirrhosis-HCC transition. Methods Expression matrices of single-cell
-
Emerging Therapeutic Strategies in The Fight Against Primary Biliary Cholangitis. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-03-16 Abigail Medford,Jonathan Childs,Ashleigh Little,Sanjukta Chakraborty,Leonardo Baiocchi,Gianfranco Alpini,Shannon Glaser
The liver has a vital role in many metabolic and regulatory processes in the body. Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is a chronic cholestatic autoimmune disease of the intrahepatic bile ducts associated with loss of tolerance to mitochondrial antigens. At this time there is no definitive cure for PBC; however, ursodeoxycholic acid (UDCA) has been shown
-
Immunomodulatory and Antiviral Therapy Improved Functional Cure Rate in CHB Patients with High HBsAg Level Experienced NA. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-03-10 Hongyu Jia,Guodong Yu,Jiong Yu,Xiaoli Zhang,Lisha Yang,Bin Wang,Jiming Zhang,Lang Bai,Xinxin Zhang,Kai Wang,Ping Zhao,Dongliang Yang,Yingren Zhao,Yanyan Yu,Yimin Zhang,Jueqing Gu,Chanyuan Ye,Huan Cai,Yingfeng Lu,Dairong Xiang,Liang Yu,Jiangshan Lian,Jianhua Hu,Shanyan Zhang,Ciliang Jin,Yida Yang
Background and Aims A functional cure, or hepatitis B virus (HBV) surface antigen (HBsAg) loss, is difficult to achieve in patients with hepatitis B virus e antigen (HBeAg)-positive chronic hepatitis B. The HBV vaccine and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been reported to help reduce HBsAg levels and promote HBsAg loss. In this prospective randomized trial, we evaluated
-
Strategies to Prevent Mother-to-child Transmission of Hepatitis B Virus. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-03-10 Palittiya Sintusek,Nasamon Wanlapakorn,Yong Poovorawan
Mother-to-child transmission (MTCT) of hepatitis B virus (HBV) is the primary cause of chronic HBV infection worldwide. MTCT prevention and antiviral treatment of infected individuals could eliminate this public health burden. Antiviral treatment of hepatitis B surface antigen (HBsAg)-positive pregnant women and immunoprophylaxis with HBV vaccine and hepatitis B immune globulin are the most effective
-
Randomized Trial of Ciclosporin with 2-h Monitoring vs. Tacrolimus with Trough Monitoring in Liver Transplantation: DELTA Study. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-03-07 Bastian N Ruijter,Akin Inderson,Aad P van den Berg,Herold J Metselaar,Jeroen Dubbeld,Maarten E Tushuizen,Robert J Porte,Wojciech Polak,Danny van der Helm,Marjolein van Reeven,Mar Rodriguez-Girondo,Bart van Hoek
Background and Aims Previous trials comparing cyclosporine and tacrolimus after liver transplantation (LT) showed conflicting results. Most used trough monitoring for cyclosporine (C0), leading to less accurate dosing than with 2-h monitoring (C2). Only one larger trial compared C2 with tacrolimus based on trough level (T0) after LT, with similar treated biopsy-proven acute rejection (tBPAR) and graft
-
Portal Hypertension Refractory Ascites Caused by Secondary Hemochromatosis. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-03-07 Jun Tie,Wen Yuan Jia,Xiaoyuan Gou
We report a patient with refractory ascites because of portal hypertension caused by hemochromatosis secondary to osteopetrosis. To our knowledge, this is the first well-documented case of this association. A 46-year-old male patient who was repeatedly infused with red blood cells for anemia secondary to osteopetrosis suffered from refractory ascites. The serum-ascites albumin gradient was 29.9 g/L
-
Vaginal Delivery and Breastfeeding Benefit Infant Immune Response to Hepatitis B Vaccine: A Prospective Cohort Study. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-03-07 Huiqing Liu,Lili Li,Yali Li,Minmin Liu,Yarong Song,Feng Ding,Xiaoshu Zhang,Jie Li
Background and Aims Natural vaginal delivery and breastfeeding favor the development of a strong immune system in infants, and the immune response of infants to vaccines is closely related to their immune system. This large prospective cohort study aimed to explore the effects of delivery and feeding mode on infant's immune response to hepatitis B vaccine (HepB). Methods A total of 1,254 infants who
-
Targeting Gut Microbiota for the Treatment of Primary Biliary Cholangitis: From Bench to Bedside. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-03-01 Li Zhang,Ling Yang,Huikuan Chu
Primary biliary cholangitis (PBC) is a complex cholestatic liver disease with an unresolved etiology. The gut microbiota is composed of a dynamic community of bacteria, archaea, fungi, and viruses that have a key role in physiological processes related to nutrition, immunity, and host defense responses. A number of recent studies found that the composition of the gut microbiota of PBC patients was
-
Performance of the Enhanced Liver Fibrosis Score, Comparison with Vibration-controlled Transient Elastography Data, and Development of a Simple Algorithm to Predict Significant Liver Fibrosis in a Community-based Liver Service: A Retrospective Evaluation. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-02-24 Tina Reinson,Janisha Patel,Mead Mathews,Derek Fountain,Ryan M Buchanan,Christopher D Byrne
Background and Aims Liver fibrosis is a key risk factor for cirrhosis, hepatocellular carcinoma and end stage liver failure. The National Institute for Health and Care Excellence guidelines for assessment for advanced (≥F3) liver fibrosis in people with nonalcoholic fatty liver disease recommend the use of enhanced liver fibrosis (ELF) test, followed by vibration-controlled transient elastography (VCTE)
-
Akkermansia muciniphila and Bifidobacterium bifidum Prevent NAFLD by Regulating FXR Expression and Gut Microbiota. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-02-22 Fulin Nian,Longyun Wu,Qiaoyun Xia,Peiying Tian,Chunmei Ding,Xiaolan Lu
Background and aims Non-alcoholic fatty liver disease (NAFLD) is closely associated with gut microbiota and has become the most common chronic liver disease worldwide, but the relationship between specific strains and NAFLD has not been fully elucidated. We aimed to investigate whether Akkermansia muciniphila and Bifidobacterium bifidum could prevent NAFLD, the effects of their action alone or in combination
-
Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021). J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-02-10 Hong You,Weijia Duan,Shuxiang Li,Tingting Lv,Sha Chen,Lungen Lu,Xiong Ma,Ying Han,Yuemin Nan,Xiaoyuan Xu,Zhongping Duan,Lai Wei,Jidong Jia,Hui Zhuang,
In 2015, the Chinese Society of Hepatology and the Chinese Society of Gastroenterology published a consensus on primary biliary cholangitis (PBC). In the past years, numerous clinical studies have been published in the field of PBC. To guide the clinical diagnosis and management of PBC patients, the Chinese Society of Hepatology invited a panel of experts to assess the new clinical evidence and formulate
-
Synchronous Double Primary Combined Hepatocellular-cholangiocarcinoma and Cholangiolocarcinoma in a Cirrhotic Liver. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-02-08 Masahiro Sakata,Koji Kitada,Rika Omote,Hiroshi Sonobe,Masashi Utsumi,Naoyuki Tokunaga,Takashi Fushimi,Ryota Nagao,Tatsuro Sakata,Toshihiko Kaneyoshi,Tatsuya Toyokawa,Masaru Inagaki
Both combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and cholangiolocarcinoma are rare primary liver cancers. cHCC-CCA is believed to originate from transformed hepatocellular carcinoma or liver stem/progenitor cells. Cholangiolocarcinoma is characterized by ductular reaction-like anastomosing cords and glands resembling cholangioles or canals containing hepatocellular carcinoma components and
-
IL2-inducible T-cell Kinase is Required for HBV-induced Type T Interferon Expression and Antiviral Response. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-02-07 Mengxin Lin,Ruyi Guo,Dawu Zeng,Jiangfu Liu,Minghui Zheng,Zhijun Su
Background and Aims Hepatitis B is a vaccine-preventable liver infection caused by the hepatitis B virus (HBV), and is seen as a serious global health problem. HBV infection induces the expression of type I interferon (IFN), including IFN-α and IFN-β, which have anti-HBV activities, and have been used for HBV treatment. IL2-inducible T-cell kinase (ITK) is a tyrosine kinase, which regulates T-cell
-
TDF Promotes Glycolysis and Mitochondrial Dysfunction to Accelerate Lactate Accumulation by Downregulating PGC1α in Mice. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-02-03 Yuxuan Luo,Zhiwei Chen,Zhao Li,Aoran Luo,Yi Zeng,Min Chen,Mingli Peng,Hong Ren,Peng Hu
-
Breath Biopsy® to Identify Exhaled Volatile Organic Compounds Biomarkers for Liver Cirrhosis Detection. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-02-02 Giuseppe Ferrandino,Giovanna De Palo,Antonio Murgia,Owen Birch,Ahmed Tawfike,Rob Smith,Irene Debiram-Beecham,Olga Gandelman,Graham Kibble,Anne Marie Lydon,Alice Groves,Agnieszka Smolinska,Max Allsworth,Billy Boyle,Marc P van der Schee,Michael Allison,Rebecca C Fitzgerald,Matthew Hoare,Victoria K Snowdon
Background and Aims The prevalence of chronic liver disease in adults exceeds 30% in some countries and there is significant interest in developing tests and treatments to help control disease progression and reduce healthcare burden. Breath is a rich sampling matrix that offers non-invasive solutions suitable for early-stage detection and disease monitoring. Having previously investigated targeted
-
Stratified Analysis of Survival Benefit for ABO-incompatible Deceased-donor Liver Transplantation: Multicenter Propensity Score-matched Study. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-02-01 Mengfan Yang,Xuyong Wei,Abdul Rehman Khan,Qiang Wei,Rui Wang,Binhua Pan,Kun Wang,Zhisheng Zhou,Di Lu,Beini Cen,Shuijun Zhang,Wenzhi Guo,Shusen Zheng,Yang Yang,Xiao Xu
Background and Aims Liver transplantation (LT) using ABO-incompatible (ABOi) grafts can extend the donor pool to a certain extent and hence reduce the waiting time for transplantation. However, concerns of the impending prognosis associated with this option, especially for patients with liver failure and higher model for end-stage liver disease (MELD) scores, who tend to be more fragile during the
-
Secondary Iron Overload and the Liver: A Comprehensive Review. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-02-01 Kanokwan Pinyopornpanish,Adisak Tantiworawit,Apinya Leerapun,Atiwat Soontornpun,Satawat Thongsawat
Iron overload is a condition involving excessive iron deposit in various organs, the liver being the main target organ for iron deposition and overload which are associated with significant liver morbidity and mortality. Iron overload can be categorized into primary and secondary causes. Primary iron overload, so-called hereditary hemochromatosis, is a well-recognized disease with available standard
-
Cardiac Syndromes in Liver Disease: A Clinical Conundrum. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-02-01 Milos Brankovic,Paul Lee,Nikolaos Pyrsopoulos,Mark Klapholz
Understanding the interaction between the heart and liver is pivotal for managing patients in whom both organs are affected. Studies have shown that cardio-hepatic interactions are bidirectional and that their identification, assessment, and treatment remain challenging. Congestive hepatopathy is a condition that develops in the setting of long-standing systemic venous congestion. If left untreated
-
IGF2-NR4A2 Signaling Regulates Macrophage Subtypes to Attenuate Liver Cirrhosis. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-01-31 Lichao Yao,Xue Hu,Mengqin Yuan,Qiuling Zhang,Pingji Liu,Lian Yang,Kai Dai,Yingan Jiang
Background and Aims Liver cirrhosis can lead to liver failure and eventually death. Macrophages are the main contributors to cirrhosis and have a bidirectional role in regulating matrix deposition and degradation. Macrophage-based cell therapy has been developed as an alternative to liver transplantation. However, there is insufficient evidence regarding its safety and efficacy. In this study, we aimed
-
Sarmentosin Induces Autophagy-dependent Apoptosis via Activation of Nrf2 in Hepatocellular Carcinoma. J. Clin. Transl. Hepatol. (IF 3.6) Pub Date : 2023-01-31 Zhitao Jiang,Liyuan Gao,Chundi Liu,Jianchun Wang,Yi Han,Jinhuo Pan
Background and Aims Hepatocellular carcinoma (HCC) is a common and deadly cancer. Accumulating evidence supports modulation of autophagy as a novel approach for determining cancer cell fate. The aim of this study to evaluate the effectiveness of sarmentosin, a natural compound, on HCC in vitro and in vivo and elucidated the underlying mechanisms. Methods Cell functions and signaling pathways were analyzed